Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
|Articles|November 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
MB07133 gets orphan drug status
MB07133 gets orphan drug status
Advertisement
SAN DIEGOMetabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.
Articles in this issue
almost 19 years ago
MT103, BiTE antibody, enters phase II testing for ALLalmost 19 years ago
Sides dig in as ESA policy debate heats upalmost 19 years ago
Ixempra gets ok for resistant breast canceralmost 19 years ago
ASCO adds Oncotype DX to marker guidelinealmost 19 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenalmost 19 years ago
Accelerated approval for Tasignaalmost 19 years ago
Oxidative stress inducer ups survival in advanced melanomaalmost 19 years ago
FDA removes partial hold on Telcyta clinical developmentalmost 19 years ago
Should all HER2+ pts receive adjuvant trastuzumab?almost 19 years ago
R-CHOP is standard of care for advanced DLBCL patientsAdvertisement
Related to this article
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus nivolumab caused no unexpected safety signals.
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and other areas in myelofibrosis.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
2
Reading a Changed Eye Examination and Impact on Therapy
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
5